Bio B2B 〉 Selective Search Results
Your Selection Setting ：Neurology；
Selective Search Results :
Pipeline & Platform 9 record(s)；
INNOPHARMAX has extensive pharmaceutical R&D experience, with former researchers who worked for the Medical and Pharmaceutical Industry Technology and Development Center in Taiwan (which is the most influential pharmaceutical technology developing organization funded by the Taiwan government), INNOPHARMAX's R&D team has been highly praised by numerous pharmaceutical
Six Genomic Technology Platforms
IVD Sequencing & NGS analysisSNP genotyping analysisGene Chip analysisFunctional genomics analysisClinical genomics analysisBioinformatics analysis
Tmax of the current extended release tablets is too long, so children lose attention in learning when they start classes in the early morning.With both advantages of immediate and extended release, the unique multi-stages hot melt capsule releasing technology is able to become effective in early stage and sustainably release the drug to maintain the efficacy.The patented Oradur® formulation
The production platform is fully compliant with medical regulations (Good Tissue Practice, GTP) in Taiwan. We have three clinical trials are going in Taiwan by now including GXHPC1, GXNPC1 and GXCPC1, indications of liver cirrhosis, stroke and osteoarthritis, respectively. In addition, we currently have a clinical trial is going in Vietnam, which is called GXIPC1 that be applied for type I diabetes
LT3001 contains a new chemical entity which is composed of a thrombolytic polypeptide and a small molecule moiety with anti-oxidation activity. In rodent disease models where LT3001 was administered outside of the “golden (3) hours” post- stroke when tPA cannot be used, it significantly reduced brain infarction, restored blood flow and improved neuronal behavior score without hemorrhage
New combination for treating Sialorrhea
• Combination of two compounds with different Mechnism of Action to reduce the secreting of saliva.• First oral treatment for sialorrhoea of Parkinson's Disease.• Results of Phase IIa study, published in the 17th International Congress of Parkinson's Disease and Movement Disorders, shows efficacy and safety.
Multiple-Phasic Release Technology (MPRT)
Through Orient Pharma's patented technology, incompatible ingredients or drugs with different release profiles can be enclosed in a single capsule or tablet for the development of new drugs.
Multi-day Transdermal Drug Delivery (MTDD)
Matrix type of design resolves API to form API/Adhesive patch, which is embedded in between Backing Layer and Release Liner. The API containing side of the patch can be adhered to the skin by tearing off the Release Liner. The patch can be designed as double layers for 1-2 days use or single layer for multiple days use.
Quantitative analysis of SMN1 and SMN2 genes based on DHPLC
Autosomal recessive spinal muscular atrophy (SMA) is a common, fatal neuromuscular disease caused by homozygous absence of the SMN1 gene in approximately 95% of patients. However, a highly homologous SMN2 gene exists in the same chromosome interval, centromeric to SMN1, and hampers detection of SMN1. We develop a rapid, simple, and highly reliable method for detecting the SMN1 deletion/conversion and